With their blockbuster obesity drugs, Eli Lilly and Novo Nordisk have uncovered a variety of ailments the incretin treatments can combat. Chalk up another new potential expansion for Lilly as it has ...

Eli Lilly said it will spend $3.5 billion to build a manufacturing plant in Pennsylvania's Lehigh Valley that will help make its next-generation obesity drugs. That includes a closely watched ...

AI could reduce pharma R&D costs by 30% to 40% and shorten timelines by one to four years. The partnership expands Lilly’s existing AI supercomputer project with Nvidia’s DGX technology. Have You read ...

Warm summer days at camp may feel far off, but they are top of mind for a dozen northeast Indiana youth camps that received welcome news this month. They were among nearly 70 organizations statewide ...

Page Six may be compensated and/or receive an affiliate commission if you click or buy through our links. Featured pricing is subject to change. Say “oui” to effortless beauty. Award-winning celebrity ...

Forbes contributors publish independent expert analyses and insights. Peter Cohan, a Boston-based senior contributor, covers stocks. Eli Lilly achieved a $1 trillion market cap, a healthcare first, ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Merck, which has claimed ...

The cornerstone of the deal is Ixo-vec, an intravitreal gene therapy currently in Phase III development for wet age-related macular degeneration. Eli Lilly made another foray into genetic medicine in ...

Lilly, Novo Nordisk and the companies chasing them all want to build on the success of Zepbound and Wegovy with newer medicines that can address their limitations. Among those weaknesses are the loss ...